1. The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions;Nauck;Lancet Diabetes Endocrinol,2016
2. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist?;Willard;JCI Insight,2020
3. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes;Hojberg;Diabetologia,2009
4. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials;Min;Diabetes Ther,2021
5. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept;Coskun;Mol Metab,2018